--- title: "Twist Bioscience Q4 revenues rise 16.9% to USD 103.7 million" description: "Twist Bioscience Corporation reported a 16.9% increase in Q4 revenues, reaching USD 103.7 million for the period ending December 31, 2025. Gross margin improved to 52.0%, up from 48.3%. The loss from " type: "news" locale: "en" url: "https://longbridge.com/en/news/274558978.md" published_at: "2026-02-02T21:16:36.000Z" --- # Twist Bioscience Q4 revenues rise 16.9% to USD 103.7 million > Twist Bioscience Corporation reported a 16.9% increase in Q4 revenues, reaching USD 103.7 million for the period ending December 31, 2025. Gross margin improved to 52.0%, up from 48.3%. The loss from operations decreased to USD 32.9 million, aided by higher revenues and reduced R&D expenses. Revenue distribution included therapeutics at USD 37.23 million and diagnostics at USD 35.32 million. Growth was driven by NGS Applications and DNA Synthesis segments, with ongoing efforts in synthetic biology and biologic drug commercialization. Twist Bioscience Corporation reported revenues of USD 103.70 million for the three months ended December 31, 2025, representing an increase of 17 percent. Gross margin improved to 52.0 percent for the period, up from 48.3 percent, primarily due to increased revenues and ongoing cost-saving initiatives. Loss from operations decreased to USD 32.90 million, driven by higher revenues and gross profit, as well as a decrease in research and development expenses, despite an increase in selling, general and administrative expenses. Net cash used in operating activities rose to USD 24.80 million. By industry, revenues for the period were distributed as follows: therapeutics USD 37.23 million, diagnostics USD 35.32 million, industry and applied USD 6.12 million, academic research and government USD 12.22 million, and global supply partners USD 12.82 million. The revenue growth was primarily attributed to the NGS Applications and DNA Synthesis and Protein Solutions segments. The company noted continued efforts in commercializing additional products in synthetic biology and biologic drug sectors, alongside leveraging its manufacturing facility in Wilsonville, Oregon. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Twist Bioscience Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001581280-26-000019), on February 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here ### Related Stocks - [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md) - [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md) - [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md) - [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md) - [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md) - [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md) - [TWST.US - Twist Bioscience](https://longbridge.com/en/quote/TWST.US.md) - [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Twist Bioscience｜8-K：2026 财年 Q1 营收 1.04 亿美元超过预期 | | [Link](https://longbridge.com/en/news/272275744.md) | | Twist Bioscience｜8-K：2026 财年 Q1 营收 1.04 亿美元超过预期 | | [Link](https://longbridge.com/en/news/274512877.md) | | Neumora Therapeutics 股票大涨，分析师认为阿尔茨海默症治疗具有上升空间 | 威廉·布莱尔将 Neumora Therapeutics（纳斯达克代码：NMRA）评级上调至 “跑赢大盘”，理由是 NMRA-511 在阿尔茨海默病激动症的积极 1b 期数据带来了有利的风险/收益比，成功概率提高至 35%。该股上涨 7.5 | [Link](https://longbridge.com/en/news/276161520.md) | | GSA Capital Partners LLP 购买了 106,167 股 10x Genomics 的股票，代码为 $TXG | GSA Capital Partners LLP 在第三季度将其在 10x Genomics (NASDAQ:TXG) 的持股比例增加了 708.9%，收购了 106,167 股，使其总持股达到 121,144 股，价值 140 万美元。其 | [Link](https://longbridge.com/en/news/276216391.md) | | 奥洛兹美医疗预计 2025 年收入增长 38%，但第四季度每股收益未达市场预期 | Halozyme 2025 年的收入增长了 38%，达到了 14 亿美元，主要得益于 ENHANZE 产品的增长。然而，第四季度调整后的每股收益为-1.20 美元，未能达到分析师的预期。公司完成了对 Elektrofi 和 Surf Bio | [Link](https://longbridge.com/en/news/276168085.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.